UTHR Maintained by RBC Capital -- Price Target Raised to $708
RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.
How this was made
The 30-second read
Why it matters
The rating and target change provide fresh guidance for traders evaluating UTHR.
Market read
A modest analyst upgrade that could influence short‑term trading decisions on UTHR.
What to watch
Insider selling and weak momentum may limit upside despite the higher target.
Background
Analyst rating update from RBC Capital with a new price target for United Therapeutics.
Ticker impact
RBC Capital maintained an Outperform rating and raised United Therapeutics' price target to $708.
potential upward pressure as investors price in the higher target
The new target reflects analyst confidence but momentum remains weak, so impact may be modest.
Market effects
May slightly boost sentiment in the biotech/healthcare sector.
Limited to U.S. markets where UTHR trades.
Minimal global impact.
Counterpoint
The price‑target raise could be premature given the stock's overvaluation.
Key entities
- companyUnited Therapeutics
Biotech firm focused on pulmonary arterial hypertension therapies.
- analystRBC Capital
Investment bank that issued the rating update.
